Print

Active Biotech AB Interim Report January - March 2011

2011-04-28

  • Laquinimod- complete results from Allegro Phase III trial presented
  • TASQ- Active Biotech and Ipsen enter into a broad partnership for the co-development and commercialization of TASQ in uro-oncology
  • ANYARA- ongoing Phase III study expected to be concluded in 2012
  • 57-57 - orphan drug status granted
  • ISI - project proceeding according to plan
  • RhuDex(TM) -preparations for continued clinical development in progress
  • Net sales SEK 2.7 M (2.8)
  • Operating loss SEK 70.9 M (loss: 51.0)
  • Loss after tax SEK 69.3 (loss: 53.5)
  • Loss per share for the period amounted to 1.02 (loss: 0.83)
  • Private placement of SEK 375 M completed

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam
CFO
Tel. +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com


pdfActive Biotech AB Interim Report January - March 2011



Back